Aug 9, 2018
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company developing potentially transformative therapies for patients affected by a range
Loading...
seen from United States
seen from Yemen
seen from United States
seen from China
seen from United States
seen from United States
seen from Canada
seen from Canada
seen from Hungary
seen from Russia
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from United States
seen from China
seen from United States
seen from Bangladesh
seen from China
Zafgen (Nasdaq:ZFGN) is a clinical-stage biopharmaceutical company developing potentially transformative therapies for patients affected by a range
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Obesity Treatment: Zafgen's New Drug Succeeds In Mid-Stage Trial For Obesity treatment, Zafgen’s new drug has succeeded in mid stage clinical trial. Zafgen’s controversial obesity drug reduced the weight of overweight diabetic patients, the second trial success in as many months for the drug on which all tests have been halted since December after... http://www.healthaim.com/obesity-treatment-zafgens-new-drug-succeeds-mid-stage-trial/41409
Obesity Treatment: Zafgen's New Drug Succeeds In Mid-Stage Trial - http://www.healthaim.com/obesity-treatment-zafgens-new-drug-succeeds-mid-stage-trial/41409
For Obesity treatment, Zafgen’s new drug has succeeded in mid stage clinical trial. Zafgen’s controversial obesity drug reduced the weight of overweight diabetic patients, the second trial success in as many months for the drug on which all tests have been halted since December after...
Zafgen Shares Nearly Double on Obesity Treatment http://investingnews.com/daily/life-science-investing/pharmaceutical-investing/zafgen-shares-nearly-double-on-obesity-treatment/
Zafgen Shares Nearly Double on Obesity Treatment
Zafgen saw its share price almost double on Wednesday, after positive data on its experimental obesity drug could convince the US Food and Drug Administration to lift a hold
Zafgen Inc. (ZFGN)
Zafgen Inc. (ZFGN)  — Steinmeyer Securities Litigation Group (SSLG) announces an investigation on behalf of Zafgen, Inc. investors (“Zafgen” or the “Company”) (Nasdaq: ZFGN) concerning the Company’s and its officers’ possible violations of federal securities laws. On October 16, 2015, Zafgen disclosed that it received verbal notice from the U.S. Food and Drug Administration that the clinical…
View On WordPress